
QNCX Stock Forecast & Price Target
QNCX Analyst Ratings
Bulls say
Quince Therapeutics Inc's strong safety record from prior clinical trials and open-label extensions reinforces confidence in its favorable toxicity profile and long-term tolerability. High patient retention rates, indicated by participants' decisions to continue in open-label extensions, signal significant interest in the therapy, which may enhance future market potential. Additionally, the company’s ambitious pipeline expansion into conditions like Duchenne Muscular Dystrophy alongside its innovative drug delivery platform suggests robust scalability and growing opportunities within precision therapeutics for rare diseases.
Bears say
Quince Therapeutics Inc reported a net loss of $13.3 million for Q3 2025, indicative of the financial challenges often faced by early-stage biotechnology firms. The company's cash and short-term investments totaled $26.3 million as of September 30, 2025, which raises concerns about its liquidity and ability to fund ongoing research and development efforts given the significant loss. Additionally, with research and development expenses reaching $8.1 million, the financial metrics suggest that the company may struggle to maintain operational stability in the long term without external financing or a substantial increase in revenue.
This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
QNCX Analyst Forecast & Price Prediction
Start investing in QNCX
Order type
Buy in
Order amount
Est. shares
0 shares